AXON vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 08, 2026

AXON

53.5
AI Score
VS
AXON Wins

MRNA

37.1
AI Score

Investment Advisor Scores

AXON

54score
Recommendation
HOLD

MRNA

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AXON MRNA Winner
Revenue 1.71B 534.00M AXON
Net Income 198.74M -2.13B AXON
Net Margin 11.6% -397.9% AXON
Operating Income 76.02M -2.20B AXON
ROE 5.4% -31.4% AXON
ROA 2.7% -19.4% AXON
Total Assets 7.48B 10.96B MRNA
Cash 597.70M 1.72B MRNA
Debt/Equity 0.47 0.09 MRNA
Current Ratio 2.15 2.29 MRNA
Free Cash Flow -55.61M -1.25B AXON

Relative Price Performance (Last 90 Days)

AXON 1M: -14.8% · 3M: -26.2% MRNA 1M: +45.3% · 3M: +188.6%

Current Technical Phase

AXON

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.9%), weak momentum, RSI 36

RSI (14): 35.8 · Price: $417.31

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (50.6% over 20 days), RSI 64

RSI (14): 63.8 · Price: $197.00

Fundamentals Snapshot

Metric AXON MRNA
Market Cap — —
Forward P/E 39.6 -41.1
Trailing P/E 173.5 —
Revenue (TTM) — —
Revenue Growth 0.4% 0.0%
Gross Margin 0.6% -0.7%
Operating Margin 0.1% -5.6%
EPS 2.34 -7.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, AXON is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.